Aurinia Pharmaceuticals ( (AUPH) ) has shared an update.
Aurinia Pharmaceuticals Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission, indicating a significant corporate event. This filing is part of the company’s regulatory compliance, reflecting its ongoing commitment to transparency and adherence to financial reporting standards, which may impact its market perception and stakeholder confidence.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a Canadian company operating in the pharmaceutical industry. It primarily focuses on developing and commercializing therapies to treat autoimmune diseases.
YTD Price Performance: -9.35%
Average Trading Volume: 1,312,832
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.14B
For a thorough assessment of AUPH stock, go to TipRanks’ Stock Analysis page.